載入中
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$36.35
+US$0.04 · +0.11%
收盤時
US$36.35
+US$0.04 · +0.11%
盤後
US$36.35
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
日內區間
目前US$36.35
52週區間
目前US$36.35
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.26億 USD | 7.01億 USD | 6.75億 USD | 6.67億 USD | 5.42億 USD |
| 銷貨成本 | 1.5億 USD | 1.7億 USD | 1.85億 USD | 1.99億 USD | 1.4億 USD |
| 毛利 | 5.77億 USD | 5.31億 USD | 4.9億 USD | 4.68億 USD | 4.01億 USD |
| 研究與開發 | 1.17億 USD | 8157.7萬 USD | 7625.7萬 USD | 8479.7萬 USD | 5554.5萬 USD |
| 銷售、一般及管理費用 | 3.69億 USD | 2.94億 USD | 2.69億 USD | 2.55億 USD | 1.99億 USD |
| 營業費用 | 5.43億 USD | 6.04億 USD | 4.03億 USD | 4.08億 USD | 3.11億 USD |
| 利息收入 | 2273.2萬 USD | 1968.9萬 USD | 1144.4萬 USD | 454.2萬 USD | 89.6萬 USD |
| 利息支出 | 1460.6萬 USD | 1656.9萬 USD | 1731萬 USD | 3557.6萬 USD | 2899.6萬 USD |
| 折舊和攤銷 | 9102.3萬 USD | 7878.5萬 USD | 7557.4萬 USD | 9150.1萬 USD | 2854.8萬 USD |
| 營業利益 | 3330.3萬 USD | −7337.1萬 USD | 8767.5萬 USD | 6002.4萬 USD | 8992.4萬 USD |
| 淨利 | 703.4萬 USD | −9956萬 USD | 4195.5萬 USD | 1590.9萬 USD | 4198萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$31.67
下跌空間 12.87%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM3749.06萬0.05%787.4億 USD0.19%US$277.9-0.37%
Avantis U.S. Small Cap Value ETFAVUV3434.69萬0.11%308.51億 USD0.25%US$119.94+0.25%
Vanguard Morningstar Total Stock Market ETFVTI3104.87萬0.00%2.3兆 USD0.03%US$381.57-0.10%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2914.9萬0.11%268.09億 USD0.33%US$37.98+0.08%
Vanguard Morningstar Small-Cap ETFVB2222.8萬0.01%1853億 USD0.03%US$288.16-0.46%
Dimensional - US Targeted Value ETFDFAT1495.4萬0.05%301.22億 USD0.33%US$67.42+0.22%
Vanguard Morningstar Small-Cap Value ETFVBR1414.23萬0.02%682億 USD0.05%US$234.71+0.12%
Fidelity Enhanced Small Cap ETFFESM1408.58萬0.21%64.1億 USD0.28%US$45.24-0.48%iShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIU.S. Small Cap Value Portfolio ETF Class SharesDFSVVanguard Morningstar Small-Cap ETFVBDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Value ETFVBRFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
